Armin Graber, Ph.D., Habil

Senior Vice President, Translational Medicine, Companion Diagnostics and Biomarkers

Armin Graber, Ph.D., Habil, is senior vice president and the head of translational medicine, companion diagnostics and biomarkers at BlossomHill Therapeutics. He has 35 years of work experience in the pharmaceutical and diagnostic industries as well as academia, with more than 160 peer-reviewed publications, books and patents. Most recently, Dr. Graber was senior vice president and head of translational medicine at Turning Point Therapeutics, which Bristol Myers Squibb acquired in August 2022. At Turning Point, he established the translational medicine department with functions for biomarkers, companion diagnostics and correlative sciences to support the global development of its clinical-stage pipeline, including repotrectinib (AUGTYRO®).

Before Turning Point, Dr. Graber was vice president and the head of research, product development, and medical affairs at Genoptix, a Novartis company. He held various global roles in translational and precision medicine at Novartis, leading the development and implementation of biomarker, correlative sciences, MRD monitoring and companion diagnostics strategies to support worldwide approvals for products, such as for the treatment of hematologic malignancies, including midostaurin (RYDAPT®), imatinib (GLEEVAC®) and nilotinib (TASGINA®), and the treatment of solid cancers such as dabrafenib (TAFINLAR®), trametinib (MEKINIST®), ceritinib (ZYKADIA®) and ribociclib (KISQALI®). He also served as vice president for translational research for BG Medicine, was CEO of Biocrates Life Sciences, chair of the Institute of Bioinformatics and Translational Research as well as the Department of Biomedical Sciences and Engineering, and chancellor and CEO of the University for Health Sciences, Medical Informatics and Technology (UMIT).

Originally from Austria, Dr. Graber received a Master of Science in technical mathematics and computer science from the Technical University of Graz, a doctorate in medical informatics and biostatistics from the University of Innsbruck and a Priv.-Doz. in bioinformatics and translational research from the UMIT.